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OBJECTIVE — The purpose of this study was to examine the effects of statin therapy on
lipoproteinparticleconcentrationsinpatientswiththemetabolicsyndrome.Changesinlipopro-
tein particle concentration may predict the risk of coronary heart disease more accurately than
lipoprotein cholesterol levels.
RESEARCH DESIGN AND METHODS — Patients with dyslipidemia and the meta-
bolic syndrome (n  318) were randomly assigned in a double-blind study comparing 10 mg
rosuvastatin (RSV), 10 mg atorvastatin, or placebo daily for 6 weeks. From weeks 6 to 12,
patients in the RSV and placebo groups received 20 mg RSV, whereas the ATV group increased
their dose to 20 mg daily. Lipoprotein particle concentrations were measured by nuclear mag-
netic resonance spectroscopy, LDL cholesterol was measured by -quantiﬁcation, and other
lipoproteins were measured by standard methods at baseline, 6 weeks, and 12 weeks. Lipopro-
tein levels were compared by analysis of covariance.
RESULTS — Statins reduced LDL particle concentration less than LDL cholesterol (30 to
38 vs. 38 to 51%). Reductions were greater with RSV than with ATV (P  0.05 for LDL
particle concentration and P  0.001 for LDL cholesterol). Most patients attained LDL choles-
terol2.59mmol/l(100mg/dl)at12weeks(80%withRSVand59%withATV;P0.003),but
only 27% of patients receiving RSV and 19% receiving ATV attained the goal of LDL particle
concentration 1,000 nmol/l (P  0.07).
CONCLUSIONS — In patients with the metabolic syndrome, statin-induced changes in
LDL cholesterol do not accurately reﬂect changes in LDL particle concentration. Consequently,
despite attainment of LDL cholesterol goals, these patients may retain considerable residual
coronary heart disease risk.
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A
lthough LDL cholesterol reduction
serves as a cornerstone of preven-
tion of coronary disease (1), the
coronaryheartdisease(CHD)riskmaybe
better predicted by measures of athero-
genic particles, such as non–HDL choles-
terol (2), apolipoprotein B (apoB) (3), or
LDL particle concentration (4–6).
Patientswiththemetabolicsyndrome
may have relatively normal LDL choles-
terol when LDL particle concentration is
elevated because these patients have a
preponderance of small, cholesterol-poor
LDL particles (7). Thus, LDL cholesterol
may underestimate risk in patients with
the metabolic syndrome (2,8). Likewise,
in men with CHD, low HDL cholesterol
(1.04 mmol/l [40 mg/dl]), and often
many other characteristics of the meta-
bolic syndrome, new CHD events were
correlatedwithhighLDLparticleconcen-
trationbutnotLDLcholesterol,andalow
HDL particle concentration was more
strongly inversely correlated with CHD
events than was HDL cholesterol (5).
This exploratory analysis of the Com-
parative Study with Rosuvastatin in Sub-
jects with Metabolic Syndrome (COMETS,
4522IL/0069) (9) compares the effects
of rosuvastatin (RSV) and atorvastatin
(ATV) on lipoprotein particle concentra-
tions and cholesterol levels in patients
with the metabolic syndrome. We sought
to determine the efﬁcacy of statin therapy
inachievingLDLcholesteroltargetssetby
the National Cholesterol Education Pro-
gram Adult Treatment Panel III (ATP III)
and the corresponding numbers of pa-
tients who achieved LDL particle concen-
tration targets below the 50th percentile
(1,300 nmol/l) and below the 20th per-
centile (1,000 nmol/l) based on values
established by the Multi-Ethnic Study of
Atherosclerosis (MESA) (10).
RESEARCH DESIGN AND
METHODS— The study population
included men and women, aged 18
years,withthemetabolicsyndromeasde-
ﬁned by ATP III criteria (1) (Table 1).
Other inclusion criteria included LDL
cholesterol 3.36–6.48 mmol/l (130–250
mg/dl) and a 10-year CHD risk score
10%. Exclusion criteria included tri-
glycerides 5.65 mmol/l (500 mg/dl),
use of lipid-lowering therapy within 6
months, CHD or other atherosclerotic
disease, diabetes, and liver dysfunction.
The study was conducted in accor-
dancewiththeprinciplesoftheDeclaration
of Helsinki and Good Clinical Practice.
Study procedures were approved by ethics
committees, and all patients provided in-
formed, written consent.
Patients were randomly assigned at
56 clinical centers in Europe and the U.S.
into a double-blind, double-dummy,
parallel-group study (9). After a 4-week
dietary lead-in period, patients were ran-
domly assigned (2:2:1) to 10 mg/day RSV
(RSV10), 10 mg/day ATV (ATV10), or
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treatment period, patients treated with
RSV10 or placebo received 20 mg/day
RSV (RSV20), and patients previously
treated with ATV10 received 20 mg/day
ATV (ATV20) for another 6 weeks.
Fasting blood samples were collected
at baseline and at 6 and 12 weeks. Li-
poprotein particle concentrations were
measuredbyautomatednuclearmagnetic
resonance spectroscopy (LipoScience,
Raleigh, NC) (10). Lipids and lipopro-
teins were measured at a central labora-
tory certiﬁed for lipid analysis by the
Standardization Program of the Centers
for Disease Control and Prevention and
the National Heart, Lung, and Blood
Institute (Medical Research Laboratories
International, Zaventum, Belgium, and
Highland Heights, KY). -Quantiﬁcation
wasperformedtoprovidethemostaccurate
measure of LDL cholesterol in the pres-
ence of high triglyceride levels. Plasma
samples were overlaid with normal saline
and ultracentrifuged (105,000g) for 18 to
22 h at 10°C; centrifuge tubes were sliced
to separate the top (density 1.006;
VLDL)andbottom(density1.006;LDL
and HDL cholesterol) fractions. The cho-
lesterol contents of the bottom fraction
and whole plasma were measured using
an automated analyzer (Hitachi 747). For
determination of HDL cholesterol, plasma
was treated with Mn
2 and heparin to pre-
cipitatechylomicrons,VLDL,andLDLcho-
lesterol. After centrifugation, the HDL
cholesterol content of the supernatant was
measured in an automated analyzer. VLDL
cholesterol was calculated as total choles-
terol from whole plasma minus (LDL 
HDLcholesterol)fromthebottomultracen-
trifugation fraction. LDL cholesterol was
calculated as (LDL  HDL cholesterol)
from the bottom ultracentrifugation frac-
tion minus HDL cholesterol from the pre-
cipitation assay. Non-HDL cholesterol was
calculated as total cholesterol from whole
plasma minus HDL cholesterol from the
precipitation assay. Triglycerides were
measured using the automatic analyzer,
and apolipoproteins were measured by
immunonephelometry.
Statistical analysis
Data from the per-protocol patient popu-
lationwereusedforthisexploratoryanal-
ysisbecauseacompletelaboratorydataset
was required for each patient. Statistical
signiﬁcance of least-squares differences
among treatment groups was determined
with an ANCOVA model that included
controls for treatment, study center, and
baseline value. The statistical signiﬁcance
of differences in goal attainment was de-
termined by the 
2 test.
RESULTS— The ﬁrst patient was en-
rolledintothestudyon16May2002,and
thelastpatientcompletedthestudyon30
September 2003. The population in-
cluded 318 patients at baseline, of whom
136 were randomly assigned to RSV10,
119 to ATV10, and 63 to placebo. At
week 6, the per-protocol population in-
cluded 278 patients (RSV10, n  122;
ATV10,n101;andplacebo,n55);at
the end of the study (12 weeks); data for
257 patients were available for analysis
(RSV20, n  166, and ATV20, n  91).
Baseline lipid and lipoprotein parameters
were well balanced among patients in the
three treatment arms (Table 2).
Effects on LDL and VLDL
Comparedwithplacebo,bothRSV10and
ATV10 signiﬁcantly (P  0.001) reduced
LDL cholesterol, LDL particle concentra-
tion, apoB, and non-HDL cholesterol
(Fig. 1) after 6 weeks of treatment. RSV
was more effective than ATV in reducing
LDLcholesterol(P0.001),LDLparticle
concentration (P  0.05), and non-HDL
cholesterol (P  0.01) after 6 and 12
weeks. With either statin, percent reduc-
tions in LDL particle concentration were
smaller than reductions in LDL choles-
terol. This difference was apparent at 6
weeks (34 vs. 45% for RSV10 and 30 vs.
38% for ATV10) and became more pro-
nounced after 12 weeks (38 vs. 50% for
RSV20 and 33 vs. 44% for ATV20). Re-
ductions in LDL cholesterol, LDL particle
concentration, non-HDL cholesterol, and
apoB did not differ substantially among
Table 1—Demographic and clinical characteristics of the study population
10/20 mg
RSV
10/20 mg
ATV
Placebo/20
mg RSV
n 136 119 63
Age (years) 58.6  9.3 58.2  9.7 58.5  9.0
Male sex 87 (64.0) 78 (65.5) 43 (68.3)
Caucasian race 134 (98.5) 116 (97.5) 60 (95.2)
BMI (kg/m
2) 30.5  3.8 31.0  3.5 30.4  4.0
Metabolic syndrome criteria
Abdominal obesity* 123 (90.4) 116 (97.5) 57 (90.5)
Triglycerides 1.70 mmol/l (150 mg/dl) 110 (80.9) 81 (68.1) 52 (82.5)
Low HDL cholesterol† 73 (53.7) 54 (45.4) 24 (38.1)
Blood pressure 130/85 mmHg 128 (94.1) 113 (95.0) 60 (95.2)
Fasting glucose 6.11–6.94 mmol/l 33 (24.3) 29 (24.4) 14 (22.2)
Data are means  SD or n (%). *Waist circumference 102 cm for men and 88 cm for women. †HDL
cholesterol 1.04 mmol/l (40 mg/dl) for men and 1.30 mmol/l (50 mg/dl) for women.
Table 2—Baseline lipoprotein levels
Parameter Rosuvastatin Atorvastatin Placebo
n 122 101 55
HDL-C (mmol/l) 1.1  0.2 1.2  0.2 1.2  0.2
HDL-P (	mol/l) 28  62 9  63 1  6
ApoA-I (mg/dl) 146  26 151  25 152  21
LDL-C (mmol/l) 4.3  0.6 4.4  0.6 4.4  0.7
Non-HDL-C (mmol/l) 5.3  0.7 5.3  0.8 5.4  0.8
Total cholesterol (mmol/l) 6.4  0.7 6.5  0.8 6.6  0.8
LDL-P (nmol/l) 1,962  383 1,869  367 2,018  440
ApoB (mg/dl) 160  24 161  26 164  28
VLDL-P (nmol/l) 109  35 104  37 105  34
Triglycerides (mmol/l) 2.3  0.8 2.1  0.7 2.5  0.9
C-reactive protein (mg/l) 2.2 2.9 2.6
DataaremeansSDormedian.HDL-C,HDLcholesterol;HDL-P,HDLparticleconcentration;LDL-C,LDL
cholesterol; LDL-P, LDL particle concentration; non-HDL-C, non-HDL cholesterol; VLDL-P, VLDL particle
concentration.
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rum triglycerides (Table 3).
Compared with placebo, RSV10 and
ATV10 signiﬁcantly (P  0.001) reduced
VLDL particle concentration and serum
triglycerides by 6 weeks (Fig. 1). The two
statinsweresimilarlyeffectiveinreducing
VLDL particle concentration and serum
triglycerides at weeks 6 and 12.
Effects on HDL
Compared with placebo, RSV10 increased
HDL particle concentration (15%) and
HDL cholesterol (10%) signiﬁcantly (P 
0.001) (Fig. 1). Although ATV10 also sig-
niﬁcantly increased HDL particle concen-
tration (6%, P  0.013 vs. placebo), it was
not more effective than placebo in increas-
ing HDL cholesterol (4%, P  0.45). RSV
wassigniﬁcantlymoreeffectivethanATVin
increasing HDL particle concentration and
HDL cholesterol after 6 and 12 weeks (P 
0.002). Neither statin showed a statistically
signiﬁcant effect on apoA-I compared with
placebo; however, increases in apoA-I were
signiﬁcantly greater with RSV than with
ATV at 6 (P  0.001) and 12 weeks (P 
0.02)(Fig.1).Inpatientswithhighbaseline
triglyceride levels, HDL cholesterol, HDL
particle concentration, and apoA-I in-
creases with ATV20 appeared higher (4–
19%) than in those with low baseline
triglycerides(1–5%)(Table3).HDLcholes-
terol, HDL particle concentration, and
apoA-I increases with RSV20 were numeri-
callygreaterthanthosewithATV20regard-
less of baseline triglyceride levels.
Goal attainment
Most patients achieved LDL cholesterol
2.59 mmol/l (100 mg/dl), but a sig-
niﬁcantly higher proportion of patients
assigned to RSV achieved this goal (P 
0.01 at 6 weeks and P  0.0001 at 12
weeks vs. ATV) (Table 4). Patients as-
signed to RSV were also more likely to
Figure 1—Least-squares mean percentage change from baseline in lipids and lipoproteins by
treatment group. 2, apoA-I; s, apoB; f, HDL cholesterol; p, HDL particle concentration;  ,
LDL cholesterol; o, LDL particle concentration; z, non–HDL cholesterol; c, triglycerides; `,
VLDL particle concentration.
Table 3—Baseline lipoprotein levels and percent change from baseline by triglyceride subgroup
Parameter
Baseline triglyceride 2.26 mmol/l Baseline triglyceride 2.26 mmol/l
Week 6 Week 12 Week 6 Week 12
RSV10 ATV10 Placebo RSV20 ATV20 RSV10 ATV10 Placebo RSV20 ATV20
n 66 64 22 80 58 56 37 33 86 33
HDL-C (mmol/l) 1.1 1.2 1.3 1.1 1.1 1.1
% change 7* 3 1 9§ 3 12†§ 4 4 14 11
HDL-P (	mol/l) 28 29 32 29 29 30
% change 12* 8 2 15§ 5 14 13 6 21 19
ApoA-I (mg/dl) 149 148 152 158 156 154
% change 4 0.02 3 6 15 § 21 6 4
LDL-C (mmol/l) 165 168 162 171 176 173
% change 47‡§ 39‡ 3 52 46 43‡ 37‡ 2 49§ 42
Non-HDL-C (mmol/l) 5.0 5.0 4.8 5.6 5.8 5.7
% change 44‡ 37‡ 2 49 43 43‡ 37‡ 1 48 42
LDL-P (nmol/l) 1,812 1,736 1,691 2,140 2,100 2,236
% change 33‡ 29‡ 1 37 32 37‡ 30‡ 2 40 35
ApoB (mg/dl) 152 153 146 169 175 176
% change 38‡ 33‡ 1 43 37 37‡ 35‡ 1 42 37
VLDL-P (nmol/l) 95 89 86 126 130 117
% change 39‡ 40‡ 5 42 44 29‡ 33‡ 4 40 40
Triglycerides (mmol/l)¶ 1.8 1.7 1.7 3.0 2.9 3.0
% change 15* 22† 1 18 24 30‡ 26† 7 30 31
*P  0.05 vs. placebo. †P  0.01 vs. placebo. ‡P  0.001 vs. placebo. §P  0.01 vs. ATV. P  0.05 vs. ATV. ¶A triglyceride concentration of 2.26 mmol/l
correspondsto200mg/dl.HDL-C,HDLcholesterol;HDL-P,HDLparticleconcentration;LDL-C,LDLcholesterol;LDL-P,LDLparticleconcentration;non-HDL-C,
non-HDL cholesterol; VLDL-P, VLDL particle concentration.
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nmol/l at 12 weeks (P  0.02 vs. ATV)
and LDL particle concentration 1,000
nmol/lat6weeks(P0.02vs.ATV).The
percentage of patients who attained LDL
particle concentration 1,300 nmol/l
was similar to that achieving LDL choles-
terol 2.59 mmol/l (100 mg/dl), but
fewer patients reached LDL particle con-
centration 1,000 nmol/l.
CONCLUSIONS — In patients with
the metabolic syndrome, statins reduced
atherogenic lipoproteins, and reductions
generally were higher with RSV than with
ATV.RSVincreasedHDLcholesterol,and
both statins increased HDL particle con-
centration compared with placebo. In-
creases in HDL cholesterol, HDL particle
concentration, and apoA-I were greater
with RSV than with ATV (P  0.001 for
all vs. ATV10; P  0.01 for HDL choles-
terolandHDLparticleconcentration,and
P  0.05 for apoA-I vs. ATV20). A higher
proportion of patients assigned to RSV
achieved LDL cholesterol 2.59 mmol/l
(100 mg/dl); however, even with
RSV20, only 27% of these patients with
the metabolic syndrome reached compa-
rably low LDL particle concentration lev-
els of 1,000 nmol/l.
In this population, the magnitude of
LDL particle concentration reduction
with statins was smaller than that of LDL
cholesterol reduction, suggesting that
LDL cholesterol may underestimate resid-
ual CHD risk in patients with the metabolic
syndrome. In contrast, in a dyslipidemic
population not selected to have the met-
abolic syndrome, modest statin-induced
reductions in LDL cholesterol (28%) and
LDL particle concentration (24%) by
pravastatin were more concordant (11).
These observations support the possibil-
ity that LDL particle goals, assessed by
nuclearmagneticresonanceorapoBmea-
surement, may offer an advantage over
LDL cholesterol goals (2,12), particularly
in patients with the metabolic syndrome.
Although the statin effect on LDL
particleconcentrationwasattenuatedin
comparison with the effect on LDL cho-
lesterol, the fractional HDL particle
concentration response was higher than
that of HDL cholesterol. ApoA-I levels
were only modestly increased (4–6%
by RSV and 1 to 2% by ATV), consis-
tent with the known heterogeneity of
HDLparticleswithregardtoapoA-Iand
lipid content (13). Thus, the observed
treatment effects could reﬂect an in-
crease in relatively cholesterol-depleted
HDL particles. Whether this cholesterol
depletion is due to higher cholesterol
ester transfer protein–mediated reverse
cholesterol transport activity or to re-
duced cholesterol uptake from the pe-
riphery is uncertain. A recent report
described the apparent dysfunction of
HDL in patients with the metabolic syn-
drome (14); thus, any mechanistic
hypothesis would not necessarily apply
to other patient groups. Restoring
HDL function may be particularly valu-
able in these patients, but the utility of
statins for this purpose remains to be
established.
Strengths of this analysis include the
randomized, blinded, and placebo-con-
trolled design and the increasing clinical
relevance of the patient population stud-
ied.Severalpossiblelimitationsshouldbe
noted.First,the12-weekassessmentsdid
not include a placebo comparator. How-
ever, the objective nature of the measure-
ments and the small magnitude of
changesobservedwithplacebointheﬁrst
6-weekperiodsuggestthatchangesby12
weeks can be attributed to statin therapy.
Second, patients in the RSV20 group in-
cludedboththosetreatedpreviouslywith
RSV10 and those given placebo previ-
ously,possiblyleadingtoheterogeneityin
clinical response. Third, the study popu-
lation was almost entirely Caucasian (392
of 401; 98%); thus, the ﬁndings may not
apply to other racial and ethnic groups.
Finally, in view of the exploratory nature
ofthisposthocanalysis,resultsshouldbe
interpreted cautiously.
The paradigm that the concentration
of atherogenic particles is a more impor-
tant determinant of cardiovascular risk
than conventional lipid measures such as
LDL cholesterol (3,15) implies that mea-
surements such as LDL particle concen-
tration or apoB may move toward the
center of future risk assessment. In nearly
all prospective studies, LDL particle con-
centration or apoB has been a stronger
predictor of cardiovascular outcomes
than LDL cholesterol. A recent analysis of
the Framingham Offspring Study showed
that LDL particle concentration was ap-
proximately twice as strongly related to
CVD incidence as was LDL cholesterol
(6). In individuals whose LDL cholesterol
and LDL particle concentration were dis-
cordant, which was deﬁned as having
above-median LDL cholesterol and be-
low-median LDL particle concentration
(or vice versa), CVD event risk was asso-
ciated more closely with LDL particle
concentration than with LDL cholesterol
(6).
Our analysis conﬁrmed that, at equal
doses, RSV was more effective than ATV
for treating dyslipidemia in patients with
themetabolicsyndrome.Forbothstatins,
the percent reduction in LDL particle
concentration was smaller than that in
LDL cholesterol, whereas, conversely,
HDL particle concentration increases
were greater than HDL cholesterol in-
creases. These ﬁndings suggest the pos-
sibility that treating patients with the
metabolic syndrome to targets based on
LDLparticleconcentrationratherthanon
LDL cholesterol may provide a more reli-
able approach to reducing residual CHD
risk, but this remains to be established.
The American Diabetes Association/
American College of Cardiology Founda-
tionconsensusconferencereportrecently
Table 4—Number and percentage of patients achieving LDL particle and LDL cholesterol
goals
Baseline 6 weeks 12 weeks
LDL-P 1,000 nmol/l
Rosuvastatin 0 30/122 (25) 45/166 (27)
Atorvastatin 0 12/101 (12) 17/91 (19)
Placebo 0 1/55 (2) —
LDL-P 1,300 nmol/l
Rosuvastatin 4/122 (3) 70/122 (57) 115/166 (69)
Atorvastatin 3/101 (3) 60/101 (59) 50/91 (55)
Placebo 3/55 (5) 1/55 (2) —
LDL cholesterol 2.59 mmol/l
Rosuvastatin 0 99/162 (61) 185/232 (80)
Atorvastatin 0 70/151 (46) 85/145 (59)
Placebo 0 1/78 (1) —
Data are n (%). LDL particle concentration (LDL-P) 1,000 nmol/l corresponds to the 20th percentile and
1,300 nmol/l to the 50th percentile of values from the MESA study (10).
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goalsforpatientswiththegreatestcardio-
metabolic risk (2). This proposal is sup-
portedbyourobservationinpatientswith
themetabolicsyndromethatLDLparticle
concentration remains elevated in many
patients who achieve LDL cholesterol
goals. Further study will be needed to de-
termine whether more stringent statin
monotherapy or combination treatment,
with the goal of further reducing LDL
particle concentration, will translate into
better outcomes in patients with the met-
abolic syndrome.
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